UNSPSC 51112608: Cyclophosphamide anhydrous

This classification denotes a nitrogen mustard compound and immunosuppressant with the molecular formula C7H15Cl2N2O2P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6UXW23996M, chemically known as 2h-1,3,2-oxazaphosphorin-2-amine, n,n-bis(2-chloroethyl)tetrahydro-, 2-oxide, but more generally known as cyclophosphamide anhydrous, which bears US NIH Compound Identifier 2907.

European Medicines Agency schedules cyclophosphamide anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06859MIG. Most nations, for tariff purposes, schedule cyclophosphamide anhydrous under HS 29349990. Cyclophosphamide anhydrous bears US NLM identifiers UMLS ID C1880207 and NCI Concept Code C61694. SMILES: C1CNP(=O)(OC1)N(CCCL)CCCL.

UNSPSC 51112608 Cyclophosphamide anhydrous is a Commodity code that captures procurement of the chemotherapy agent cyclophosphamide in anhydrous form. State and local governments acquire this pharmaceutical under the code primarily through health departments, hospital systems, and correctional health services for use in cancer treatment protocols and select immunosuppressive therapies. The work involves sourcing the active pharmaceutical ingredient or finished pharmaceutical preparation to clinical specifications, often bundled with procurement of related oncology supplies and pharmacy services.

The recent-opportunities block contains no posted state and local solicitations under this code as of the date provided, limiting visibility into current issuing-body mix, geographic concentration, or representative recent RFP, RFQ, IFB, or ITB activity. Cyclophosphamide procurement typically occurs through standing pharmaceutical supply agreements, group purchasing organization contracts, or routine hospital pharmacy requisitions rather than formal competitive notices, which may explain the absence of visible recent opportunities in state and local notice systems. Firms pursuing this commodity should monitor health system cooperative purchasing platforms and state pharmacy benefit manager channels for demand signals and contracting schedules.